Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
etoposide oral
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(33)
News
Trials
Company:
Generic mfg.
Drug class:
Topoisomerase II inhibitor, DNA inhibitor
Related drugs:
‹
doxorubicin hydrochloride (87)
etoposide IV (53)
pegylated liposomal doxorubicin (31)
epirubicin (29)
daunorubicin (20)
cytarabine/daunorubicin liposomal formulation (19)
idarubicin hydrochloride (16)
mitoxantrone (16)
dactinomycin (8)
teniposide (5)
MM-302 (4)
pixantrone (4)
non-pegylated liposomal doxorubicin (3)
RTA 744 (1)
pegylated liposomal doxorubicin (1)
IT-141 (1)
SGN-15 (1)
VLS-211 (1)
zoptarelin doxorubicin (1)
INNO-206 (0)
amsacrine (0)
amrubicin (0)
MNPR-201 (0)
NSC311152 (0)
dexrazoxane (0)
doxorubicin liposomal (0)
SA033 (0)
mitoxantrone liposomal (0)
AVA6000 (0)
2X-111 (0)
HF158K1 (0)
H-ferritin–nanocaged doxorubicin (0)
MNPR-202 (0)
NP-ACT D (0)
non-pegylated liposomal doxorubicin (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
THE001 (0)
lyso-thermosensitive liposomal doxorubicin (0)
tirapazamine (0)
valrubicin (0)
idronoxil (0)
trabectedin (24)
estramustine (0)
laromustine (0)
IPdR (0)
doxorubicin hydrochloride (87)
etoposide IV (53)
pegylated liposomal doxorubicin (31)
epirubicin (29)
daunorubicin (20)
cytarabine/daunorubicin liposomal formulation (19)
idarubicin hydrochloride (16)
mitoxantrone (16)
dactinomycin (8)
teniposide (5)
MM-302 (4)
pixantrone (4)
non-pegylated liposomal doxorubicin (3)
RTA 744 (1)
pegylated liposomal doxorubicin (1)
IT-141 (1)
SGN-15 (1)
VLS-211 (1)
zoptarelin doxorubicin (1)
INNO-206 (0)
amsacrine (0)
amrubicin (0)
MNPR-201 (0)
NSC311152 (0)
dexrazoxane (0)
doxorubicin liposomal (0)
SA033 (0)
mitoxantrone liposomal (0)
AVA6000 (0)
2X-111 (0)
HF158K1 (0)
H-ferritin–nanocaged doxorubicin (0)
MNPR-202 (0)
NP-ACT D (0)
non-pegylated liposomal doxorubicin (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
THE001 (0)
lyso-thermosensitive liposomal doxorubicin (0)
tirapazamine (0)
valrubicin (0)
idronoxil (0)
trabectedin (24)
estramustine (0)
laromustine (0)
IPdR (0)
›
Associations
(33)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Thymic Carcinoma
No biomarker
Thymic Carcinoma
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
carboplatin + etoposide oral + bendamustine
Sensitive: A2 - Guideline
carboplatin + etoposide oral + bendamustine
Sensitive
:
A2
carboplatin + etoposide oral + bendamustine
Sensitive: A2 - Guideline
carboplatin + etoposide oral + bendamustine
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
ifosfamide + etoposide oral + mitoxantrone
Sensitive: A2 - Guideline
ifosfamide + etoposide oral + mitoxantrone
Sensitive
:
A2
ifosfamide + etoposide oral + mitoxantrone
Sensitive: A2 - Guideline
ifosfamide + etoposide oral + mitoxantrone
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
No biomarker
T Acute Lymphoblastic Leukemia
No biomarker
T Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
No biomarker
Merkel Cell Carcinoma
No biomarker
Merkel Cell Carcinoma
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.